

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/161939 A1

(51) International Patent Classification:

A61K 38/26 (2006.01) *A61K 47/36* (2006.01)
A61K 38/00 (2006.01) *A61K 47/38* (2006.01)
A61K 47/12 (2006.01) *A61K 9/00* (2006.01)
A61K 9/20 (2006.01) *A61P 3/10* (2006.01)

Phillip M.; 5 David Alro'i Street, Building 1, Apt. 35,
9210806 Jerusalem (IL).

(74) **Agent: EHRlich, Gal et al.**; G. E. EHRlich (1995)
LTD., Sky Tower, 13th Floor, 35 HaMasger Street,
6721407 Tel Aviv (IL).

(21) International Application Number:

PCT/IL2023/050197

(22) International Filing Date:

23 February 2023 (23.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/313,365 24 February 2022 (24.02.2022) US

(71) **Applicant: ENTERA BIO LTD.** [IL/IL]; Jerusalem Bio
Park, Hadassah Ein-Kerem, P.O. Box 12117, 9112002
Jerusalem (IL).

(72) **Inventors: BURShteIN, Gregory**; 71/8 Kislev Street,
7177625 Modiin (IL). **ITIN, ConstantIN**; 24A/4 HaBosem
Street, 9076924 Mevaseret-Zion (IL). **GALITZER, Hillel**;
43 Slav Street, 7681200 Yad Binyamin (IL). **SCHWARTZ,**

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) **Title:** FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF
GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF

(57) **Abstract:** A pharmaceutical composition is described herein, which comprises
a therapeutically active agent, an absorption enhancer, and a polymer comprising
a plurality of alkaline groups. The therapeutically active agent is a glucagon-like
peptide- 1 and/or glucagon-like peptide- 1 receptor agonist. A concentration of the
polymer in the composition is at least 10 weight percent of the total weight of the
composition. The absorption enhancer is preferably a substituted or non- substituted
fatty acid or a salt thereof. Further described herein are methods of treating a con-
dition treatable by the therapeutically active agent, comprising orally administering
the pharmaceutical composition.

SSG




FIG. 4A

WO 2023/161939 A1

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*